DDInter1638 DDInter1628
Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Samarium (153Sm) lexidronam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Foscarnet
Foscarnet {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Altretamine
Altretamine {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Thrombocytopenia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Bexarotene {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Trifluridine
Trifluridine {u} (Compound) upregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Bexarotene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Trifluridine
Trifluridine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Fluorouracil
Fluorouracil {u} (Compound) binds {v} (Gene) UMPS
UMPS {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Trifluridine
Trifluridine {u} (Compound) downregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Temozolomide
Temozolomide {u} (Compound) downregulates {v} (Gene) CHMP4A
CHMP4A {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Samarium (153Sm) lexidronam {u} may lead to a major life threatening interaction when taken with {v} Carfilzomib
Carfilzomib {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Ruxolitinib (Compound)
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Altretamine and Altretamine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Ruxolitinib (Compound)
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is downregulated by Ruxolitinib (Compound)
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Fluorouracil and Fluorouracil (Compound) binds UMPS (Gene) and UMPS (Gene) is upregulated by Ruxolitinib (Compound)
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ruxolitinib (Compound)
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Temozolomide and Temozolomide (Compound) downregulates CHMP4A (Gene) and CHMP4A (Gene) is downregulated by Ruxolitinib (Compound)
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ruxolitinib (Compound)